news & insights
Advancing the future of oncology through data, science, and discovery.
Stay up to date on how Pathos AI is transforming oncology drug development — from major funding milestones and clinical advancements to industry collaborations that shape the future of biopharma.
By Jeremy Fodor
•
August 4, 2026
NEW YORK, August 3rd, 2026 (GLOBE NEWSWIRE) — Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies, today announced a licensing agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (“Alphamab”), a wholly-owned subsidiary of Alphamab Oncology (Stock Code: 9966.HK), on JSKN016, a first-in-class (FIC) TROP2/HER3 bispecific antibody-drug conjugate (ADC) independently developed by Alphamab. Pursuant to the licensing agreement, Alphamab granted Pathos an exclusive license to research, develop, manufacture and commercialize JSKN016 in territories outside the Chinese Mainland, Hong Kong, Macau and Taiwan, with Pathos bearing all related development and commercialization costs and expenses under the agreement. Alphamab retains its full and exclusive rights to develop, manufacture and commercialize JSKN016 in the Chinese Mainland, Hong Kong, Macau and Taiwan. Under the terms of the agreement, Alphamab is entitled to receive a non-refundable upfront payment of US$125 million and milestone payments based on the achievement of certain development and commercialization milestones, totaling up to US$2,093 million, as well as tiered royalties at high-single digit to low-double digit percentage rates according to aggregate annual net sales in the licensed territories.
By Jeremy Fodor
•
August 4, 2026
Pathos assumes responsibility for early clinical development of AZD4241, utilizing its AI-driven Foundry platform to drive patient stratification and trial design.
May 6, 2026
Transaction marks one of the first clinical-stage oncology acquisitions sourced, evaluated, and executed through an AI-powered drug development platform
Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
May 15, 2025
New York, NY, May 15th, 2025 (GLOBE NEWSWIRE) — Pathos AI, ( www.pathos.com ), a leading AI-driven biotech company applying cutting-edge artificial intelligence to drug development, today announced its $365 million Series D financing, bringing its post-money valuation to approximately $1.6 billion. This financing marks a major milestone for Pathos as it expands its AI-enabled platform to drive greater speed, precision, and success in oncology drug development. The proceeds will support advancement of the company’s clinical-stage pipeline and continued investment in its proprietary AI Foundation Model purpose-built for oncology. As part of this next phase, Pathos is developing the largest multimodal foundation model in oncology. This groundbreaking effort leverages deep clinical, molecular, and imaging data to improve clinical asset selection, clinical trial design, biomarker discovery, and therapeutic innovation across the oncology landscape. “Pathos was founded to transform drug development by harnessing the full potential of multimodal data and AI,” said Iker Huerga, CEO of Pathos AI. “With this financing, we’re building one of the most advanced AI engines, designed to accelerate development, deepen clinical insight, and ensure the right therapies reach the patients who need them most.” Founded to accelerate innovation in oncology, Pathos is pioneering a new model for AI-enabled drug development. One that leverages multimodal data, advanced Artificial Intelligence, and deep clinical insight to bring new therapies to patients faster. With a strong focus on Artificial Intelligence, clinical development, and clinical execution, Pathos is committed to improving patient outcomes by accelerating the path from molecule to medicine.
the future of biopharma
Pathos is redefining what is possible in precision oncology.
see our pipeline
meet the team
